BI 1291583
Alternative Names: BI-1291583Latest Information Update: 24 Jun 2025
At a glance
- Originator Boehringer Ingelheim
- Class Antibronchitics
- Mechanism of Action Dipeptidyl peptidase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bronchiectasis
Most Recent Events
- 07 Jun 2025 Boehringer Ingelheim plans a phase I safety and pharmacokinetics study (in healthy participants and those with mild, moderate and severe hepatic impairment) in USA (PO) in June 2025 (NCT07023354)
- 14 May 2025 Boehringer Ingelheim completes a phase I trial (In volunteers) in Germany (PO) (NCT06631417)
- 29 Apr 2025 Boehringer Ingelheim initiates enrollment in a phase I drug-drug interaction trial(In volunteers) in Germany (PO) (NCT06917872)(EudraCT2024-515795-12-00)